NextCell CEO Mathias Svahn explains the latest results from ProTrans-YOUNG and his vision for the way forward

April 15, 2025

NextCell Pharma (“the company” or “NextCell”) has published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discusses with Mathias questions regarding the latest results from ProTrans-YOUNG and NextCell's participation at the International Diabetes Congress in Bangkok 7-10 April. The interview is now available with English subtitles on NextCell's website

https://www.nextcellpharma.com/nyheter#foretagspresentationer


Transcript from the interview, non-official translation and in part:

  1. You published the subgroup analysis yesterday, and it was received rather lukewarmly by shareholders, to say the least. Could you explain a bit more about why there was no observed difference between the active ProTrans-treated group and the placebo group in this dataset?
     

Yes, there are several factors that likely contributed. We are intervening very early in the disease progression, enrolling patients within a maximum of six months after diagnosis. In practice, this has ranged from four to just over twenty weeks post-diagnosis.

Many of them are still in the honeymoon phase and have high insulin levels. That’s precisely what we are targeting — we want to intervene as early as possible, when there is still significant insulin production to preserve.

This honeymoon phase, or remission phase as it’s often called, is a period following diagnosis that can be seen as a temporary reprieve in the disease process where immune activity decreases, allowing the beta cells to produce insulin, meaning patients in this phase have good blood sugar control and require significantly less insulin. But this phase eventually ends.

In the age group we've enrolled here, 12–18 years, the remission phase typically lasts six to twelve months, but there is a great deal of variation — and that’s exactly what we’re seeing in our patient group, especially in the placebo group.

Some patients had a short or negligible honeymoon phase, while others remain actively in this stage of the disease. With such large variations, it becomes very difficult to demonstrate an effect on a group level. In the placebo group, for instance, we have three patients with elevated insulin production. Unfortunately, they will undoubtedly lose this over time, and that’s when we expect to see significant differences.

What occurs during the remission phase is exactly what we aim to achieve with our treatment — to halt the autoimmune attack.  When untreated patients begin to lose their insulin production, we hope that our treatment will keep patients in the remission phase, potentially as long as we’ve seen in adults — at least five years, and hopefully for life.

What we can already say is that the patients in the ProTrans group appear more stable. And this is very much in line with what we’ve seen in adult studies, where we also had a more homogeneous population treated with ProTrans compared to placebo.

In this first readout, placebo patients had on average seventy-three percent of their insulin production remaining.  The expected progression for this age group should be somewhere between 35 and 50 percent, so we’re seeing very high levels in this study. But most importantly, it’s a matter of time.
 

  1. The stock market viewed the results as a disappointment, but do you consider the results disappointing?

No, it’s not a disappointment. In fact, this is exactly when we want to treat patients. It rather suggests that our timing is right — we want to intervene this early to help patients retain as much insulin production as possible, for as long as possible. To keep them in the remission phase for as long as we can.

We’re not seeing a difference because, currently, there’s no active autoimmune activity. We’re dealing with a low-activity disease state that will eventually progress, but the fact that we don’t see a difference during the remission phase is not something I’m disappointed about.

We also have robust data from the adult study, so I’m confident that the treatment effect will appear. Looking at the next age group, 7–11 years, we’re dealing with a more aggressive and faster disease progression.

There, we are likely to observe a treatment effect already after twelve months, as the expected honeymoon phase is shorter and with less variation — it usually lasts only three to six months. So, no — this is not a disappointment.  Perhaps the readout should have been scheduled later, to avoid making the market nervous.
 

  1. You touched on the adult studies, but could you go into more detail on how the results differ from those seen in adult trials?

In the adult study, we included patients within two years of diagnosis. That’s significantly longer than the six months used in the paediatric study.

We are seeing long-lasting treatment effects that are robust, where nearly the entire patient population is in remission, and we have five-year data following a single infusion of ProTrans — with patients retaining almost sixtyper cent of their insulin production after five years.

We also have six-year data after two infusions, where two out of three patients actually had increased insulin production. By identifying patients this early, we hope to preserve the high insulin levels they still have.

The adolescents clearly start at higher levels than many of the adults in these studies.  We have very stable and robust data from previous studies, and we’re seeing clear signs that this will work in adolescents too.
 

  1. Could you tell us a bit more about what these results mean for the company’s long-term strategy, and perhaps the road ahead for the younger age group whose readout is expected next year?

Professor Per-Ola Carlsson and his study team are now in the process of enrolling the last patients in the younger age group. Before the summer, treatment will likely be completed, which means we will have one-year data after summer 2026.

Our long-term strategy remains unchanged. We aim to take ProTrans through phase III together with a partner, to treat the full age range of 7 to 40 years. No changes.

Additionally, we have a platform technology that gives us the opportunity to expand our clinical trial programme to include more indications. We see great value in this collaborative approach with academia, both within type 1 diabetes and potentially in other indications as well.
 

  1. You mentioned Per-Ola Carlsson. Have you received any comments from him on the outcome?

No, this is not a statistical or scientific analysis — it was an administrative subgroup analysis to support our planning and dialogue with potential partners. Our permit from the medical products agency states that we should not inform the investigators of the results or go into detail.

However, since we are a public company, we were required to issue a press release regardless. But we have not had any in-depth dialogue with the investigator.
 

  1. Let’s turn briefly to the financial side of the company. You have an outstanding warrant, and of course the conditions for that may now shift somewhat. What happens if the outcome here does not meet your expectations?**

We are on a solid financial foundation, with very low operating costs and a strong scientific programme.
If you consider the fact that we are running five clinical trials with ProTrans, that places us in a truly unique position.

We also have our subsidiaries — we are not a single-focus company. We have Cellaviva, which has generated revenue since 2015 and is the largest stem cell bank in the Nordics. And we are in the process of launching our quality analysis company, QVance, where we hope to onboard clients already by the end of the year.  

We have breadth, and that gives us significant resilience and flexibility, even in a more challenging financial climate.
 

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma


For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se


Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser

The company's shares are listed on the Nasdaq First North Growth Market.
RedEye AB is assigned as Certified Adviser.

About NextCell Pharma AB

NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes. NextCell owns Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell also owns QVance which will offer quality control analytics for advanced therapy developers. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology.

Download attachmentRead full press release on Cision (external link)
2019-04-26
NextCell Pharma AB comments on the trading halt of 25 April 2019
With respect to Spotlight Stock Market’s decision on 25 April 2019 to halt trading in NextCell Pharma AB's share, the stock market has, in accordance with its regulations, ordered the company to comment on the trading halt. Discussions are currently underway between the boards of NextCell Pharma AB and Idogen AB regarding a potential merger. The structure being discussed would entail that NextCell Pharma AB makes a bid for all of the shares in Idogen AB and in turn will offer its own shares as a means of payment. At the time of the press release, the dialogue between the companies has only
With respect to Spotlight Stock Market’s decision on 25 April 2019 to halt trading in NextCell Pharma AB's share, the stock market has, in accordance with its regulations, ordered the company to comment on the trading halt. Discussions are currently underway between the boards of NextCell Pharma ...
Read moreRead more
2019-04-05
NextCell's biobank Cellaviva has received permission from IVO to handle stem cells from adipose tissue
NextCell Pharma AB ("NextCell") announces today that its biobank Cellaviva has been granted an extended permit from the Health and Care Inspectorate (IVO), to also handle and store stem cells from adipose tissue. The decision enables the company to launch its new service, stem cell saving for adults. The company has previously been authorized by IVO to operate a tissue establishment using cells from the umbilical-cord and umbilical-cord-blood from newborns and operates a biobank for family saving of these cells. The extended approval state of fat-derived stem cells means for the fat-derived
NextCell Pharma AB ("NextCell") announces today that its biobank Cellaviva has been granted an extended permit from the Health and Care Inspectorate (IVO), to also handle and store stem cells from adipose tissue. The decision enables the company to launch its new service, stem cell saving for adu...
Read moreRead more
2019-03-29
NextCell and Cellaviva are highlighted by KI Innovations
The stem cell company NextCell Pharma (“NXTCL”) announces that the company and its stem cell bank Cellaviva are highlighted by Karolinska Institutet Innovations as a positive example in its Jubilee book “20 year of innovation @ Karolinska Institutet”. Of nearly 400 innovations, NextCell and a further 19 examples have been selected to represent the social benefits that research of KI has contributed during the past 20 years. Cellaviva was founded by researchers at Karolinska Institutet with help from Karolinska Institutet Innovations AB. The company became the first private stem cell bank in
The stem cell company NextCell Pharma (“NXTCL”) announces that the company and its stem cell bank Cellaviva are highlighted by Karolinska Institutet Innovations as a positive example in its Jubilee book “20 year of innovation @ Karolinska Institutet”. Of nearly 400 innovations, NextCell and a fur...
Read moreRead more
2019-03-22
NextCell continuous to strengthen development and collaborative activities
NextCell Pharma AB ("NextCell") announces today, that during the last few months the company has engaged in an array of valuable activities and collaborations. NextCell is active in the “SweLife ATMP health economics and business models” project led by RISE and the “Visions Driven Health” project, both funded by Vinnova. The work conducted in the projects is a collaborative effort between different types of stakeholders, such as SMEs, big pharma and county councils, all with the common goal of improving the Swedish conditions for innovative cell therapies. The latest development is that
NextCell Pharma AB ("NextCell") announces today, that during the last few months the company has engaged in an array of valuable activities and collaborations. NextCell is active in the “SweLife ATMP health economics and business models” project led by RISE and the “Visions Driven Health” project...
Read moreRead more
2019-02-22
NextCell continues to develop
NextCell Pharma AB ("NextCell") gives the market updated information before its presentation at ProHearing later today by CEO, Mathias Svahn. Recruitment of patients with type-1 diabetes in the Phase II part of the ProTrans-1 clinical trial with the drug candidate ProTrans is ongoing. An application for a new trial, ProTrans-repeat, has been submitted and Cellaviva's customer inflow has been increasing. ProTrans-1, NXTCL's ongoing clinical trial for the treatment of type-1 diabetes, is divided into two parts, the first being a three-step dose escalation with three patients in each step, a
NextCell Pharma AB ("NextCell") gives the market updated information before its presentation at ProHearing later today by CEO, Mathias Svahn. Recruitment of patients with type-1 diabetes in the Phase II part of the ProTrans-1 clinical trial with the drug candidate ProTrans is ongoing. An applicat...
Read moreRead more
2019-02-12
NextCell listed on the Life Science Hotlist
NextCell Pharma AB ("NXTCL") announces that Invest Stockholm has now placed NXTCL on the Life Science Hotlist. The Stockholm-Uppsala Life Science Investment Hotlist is curated by Invest Stockholm and lists the most promising and innovative companies active in the field of life science. NXTCL with both its stem cell banking and drug development business is an ideal candidate for this list. The company develops novel treatments with stem cells from the umbilical cord. In umbilical cord and umbilical cord tissue there are young and viable stem cells that can be collected without any medical
NextCell Pharma AB ("NXTCL") announces that Invest Stockholm has now placed NXTCL on the Life Science Hotlist. The Stockholm-Uppsala Life Science Investment Hotlist is curated by Invest Stockholm and lists the most promising and innovative companies active in the field of life science. NXTCL with...
Read moreRead more
2019-02-07
NextCell´s CEO invited speaker at National conference on Clinical Studies
NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 2019 National Conference on Clinical Studies. The conference, which is held in Malmö and arranged by the national initiative Clinical Studies Sweden, a collaboration between Vetenskapsrådet (Swedish Research Council) and Sweden´s six healthcare regions, brings together researchers, politicians, and others who are active in the Life Science area. The scope of the event is knowledge exchange and networking, with the topic for the year being “The Value of Clinical studies”. Examples of issues
NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 2019 National Conference on Clinical Studies. The conference, which is held in Malmö and arranged by the national initiative Clinical Studies Sweden, a collaboration between Vetenskapsrådet (Sw...
Read moreRead more
2019-02-05
Saving of stem cell from births increases significantly for NextCell´s biobank Cellaviva
Stem cell company NextCell Pharma AB (”NXTCL”) announces that Cellaviva’s sales has increased significantly from November 2018 to January 2019, as compared to the corresponding months previous year. It is partly a result of an increasing interest in stem cell saving in Sweden, and partly due to the expansion into Denmark. Cellaviva offers new parents the opportunity to save their child´s stem cells for therapeutic treatment of diseases the family has suffered from, or risk being affected of in the future. Stem cells are collected from the umbilical cord after the umbilical cord has been cut
Stem cell company NextCell Pharma AB (”NXTCL”) announces that Cellaviva’s sales has increased significantly from November 2018 to January 2019, as compared to the corresponding months previous year. It is partly a result of an increasing interest in stem cell saving in Sweden, and partly due to t...
Read moreRead more